Folotyn for Non-Hodgkin's Lymphoma Waldorf MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Krishan Mathu, MD
(301) 645-4242
3500 Old Washington Rd Ste 102
Waldorf, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Boris Naydich, MD
(301) 705-5802
11340 Pembrooke Sq Ste 201
Waldorf, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Kemerovskij Med Inst, Kemerovo, Russia
Graduation Year: 1973

Data Provided by:
Karen Jane Hoffmeister, DO
Waldorf, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Philadelphia Coll Of Osteo Med, Philadelphia Pa 19131
Graduation Year: 1984

Data Provided by:
Krishan Murari Mathur, MD
(301) 843-6040
PO Box 2729
La Plata, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: S M S Med Coll, Univ Of Rajasthan, Jaipur, Rajasthan, India
Graduation Year: 1977

Data Provided by:
Deepnarayan Tiwarri
(301) 868-7911
8926 Woodyard Rd
Clinton, MD
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
M Ashraf Meelu, MD
(301) 638-1007
10 Saint Patricks Dr Ste 408
Waldorf, MD
Specialties
Oncology (Cancer)
Gender
Male
Languages
Panjabi, Urdu
Education
Medical School: Punjab Med Coll, Univ Of Punjab, Faisalabad, Pakistan
Graduation Year: 1980
Hospital
Hospital: St Marys Hospital, Leonardtown, Md; Southern Maryland Hospital, Clinton, Md; Calvert Mem Hosp, Prnc Frederck, Md; Civista Med Ctr, La Plata, Md; Ft Washington Med Ctr, Ft Washington, Md
Group Practice: Southern Maryland Oncology

Data Provided by:
Ashima Saini
(301) 705-5802
11340 Pembrooke Sq
Waldorf, MD
Specialty
Radiation Oncology

Data Provided by:
Sarah A Leonhard
(301) 888-2233
13605 Baden Westwood Road
Brandywine, MD
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Laxmi Narain Berwa, MD
(301) 868-9066
7700 Old Branch Ave Ste C101
Clinton, MD
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: All India Inst Of Med Sci, Ansari Nagar, New Delhi, Delhi, India
Graduation Year: 1970
Hospital
Hospital: Southern Maryland Hospital, Clinton, Md

Data Provided by:
Jose L Mendoza
(301) 868-7911
8926 Woodyard Rd
Clinton, MD
Specialty
Hematology / Oncology

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com